Olpasiran
amgen
[]
exciting results! #oceanadose trial: up to 95% reduction in lp(a) levels in secondary prevention patients! generally appears safe and well tolerated. #aha22 
Preventive Cardiologist @DukeHeartCenter | Assistant Professor | Alum of @ClevelandClinic @HopkinsMedicine | Father and Husband | Tweets are my own